Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page’s footer revision indicator was updated from v3.5.0 to v3.5.3, reflecting a change in the site/version display rather than any study information.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe study results section now includes posted results data (ORR by RECIST v1.1 with 18-month follow-up) and related dates/documents, and Cohort 3 has been renamed from 'Safety and Tolerability' to 'Tolerability' with a 100-day dosing assessment.SummaryDifference2%

- Check45 days agoChange DetectedResults Submitted is now displayed and the page revision updated to v3.5.0, replacing the previous No Results Posted and revision v3.4.3.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision updated: from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check80 days agoChange DetectedAdded Fallopian tube cancer to the listed conditions and introduced the Genetic and Rare Diseases Information Center as a resource; updated page revision from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check87 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1, indicating a minor platform update. This change does not affect study content or page layout; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.